Abstract:Abstract Background: Emerging evidence has shown that genetic factors can interact with host factors to influence patient's clinical outcomes. Inflammatory biomarkers have been identified as prognostic factors independent of tumor stage. To test the hypothesis that genetic variants in inflammation-related genes may modulate clinical outcome in non-small cell lung cancer (NSCLC) patients, we conducted a three-stage study, including an initial discovery phase and two validation phases. Methods: In the discovery phase, we analyzed the association between 19,458 SNPs in inflammation-related genes and SNPs from GWAS risk analysis, and clinical outcomes in 1,408 NSCLC patients. In the validation phases, the significant SNPs (p<0.05) were first validated in an additional 1,104 NSCLC patients from MD Anderson and then validated in 978 NSCLC patients from Harvard University. Meta-analysis was used to summarize the combined effect of each SNP in all three stages. Results: A total of 16 SNPs were identified as top candidate predictors of respective outcomes after showing consistent associations in all three stages. Among them, 5 SNPs were associated with overall survival in the entire populations. The most significant SNP is located on chromosome 6 (discovery: HR=1.49, 95%CI=1.10-2.01, P=0.010; combined validation: HR=1.45, 95%CI=1.17-1.78, P=0.001; all combined: HR=1.46, 95% CI=1.23-1.73, P=1.59×10-5). Five SNPs were associated with overall survival in late stage unresectable patients receiving chemotherapy. The most significant SNP, located on chromosome 13, consistently showed increased risk of death in all three phases (discovery: HR=1.40, 95%CI=1.09-1.81, P=0.010; combined validation: HR=1.36, 95%CI=1.14-1.63, P=0.001; all combined: HR=1.37, 95% CI=1.19-1.59, P=2.26×10-5). Six SNPs were consistently associated with progression in early stage patient receiving surgery only. The top SNP was on chromosome 1 with protective effect against developing progression in all three phases (discovery: HR=0.52, 95%CI=0.32-0.86, P=0.033; combined validation: HR=0.63, 95%CI=0.49-0.82, P=0.001; all combined: HR=0.62, 95% CI=0.5-0.79, P=5.47×10-5). To our knowledge, this is the first study to systematically evaluate the association of genetic variations in major inflammation genes and NSCLC patients’ clinical outcomes with a multi-stage design using two of the largest lung studies in the US. Our study provides evidence that genetic variations in inflammation genes may affect clinical outcomes in NSCLC patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4662. doi:10.1158/1538-7445.AM2011-4662

Whole-genome Sequencing Reveals Genomic Signatures Associated with the Inflammatory Microenvironments in Chinese NSCLC Patients

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Distinct Patterns of Somatic Genomic Alterations and Mutational Signatures in Central and Peripheral-Type Small-Cell Lung Cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

The Co-Mutation of EGFR and Tumor-Related Genes Leads to a Worse Prognosis and a Higher Level of Tumor Mutational Burden in Chinese Non-Small Cell Lung Cancer Patients

Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis

Clinical and Genomic Features of Chinese Lung Cancer Patients with Germline Mutations

Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Different gene alterations in patients with non-small-cell lung cancer between the eastern and southern China

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Prognostic biomarkers correlated with immune infiltration in non‐small cell lung cancer

Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study

Comparative Study of the Genomic Landscape and Tumor Microenvironment among Large Cell Carcinoma of the Lung, Large Cell Neuroendocrine of the Lung, and Small Cell Lung Cancer

Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung

Genomic Characteristics of Driver Genes in Chinese Patients with Non‐small Cell Lung Cancer

Abstract 4662: Genetic Predictors of Clinical Outcomes for Patients with Non-Small Cell Lung Cancer